Genetic Technologies (ASX:GTG) completed the sale of AffinityDNA and EasyDNA to Endeavor DNA for AU$525,000, according to a Monday filing with the Australian bourse.
Endeavor has an option to purchase two of Genetic Technologies' subsidiaries that employ persons involved in conducting the acquired businesses, exercisable within four weeks after completion, the filing said.
Meanwhile, the molecular diagnostics company expects the total quantum of creditor claims to exceed that of funds held and any potential future asset recoveries. There will also likely be a shortfall to unsecured creditors. The future of the company will be decided at a meeting with creditors on Feb. 26, including either to enter into liquidation or execute a deed of company arrangement.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。